BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32205537)

  • 1. Local Ablative Therapies for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
    Jairam V; Park HS; Decker RH
    Cancer J; 2020; 26(2):129-136. PubMed ID: 32205537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer.
    Kim C; Hoang CD; Kesarwala AH; Schrump DS; Guha U; Rajan A
    J Thorac Oncol; 2017 Feb; 12(2):179-193. PubMed ID: 27780780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oligometastatic Disease and Local Therapies: A Medical Oncology Perspective.
    Hafez N; Gettinger S
    Cancer J; 2020; 26(2):144-148. PubMed ID: 32205539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical treatment of oligometastatic non-small cell lung cancer.
    Pfannschmidt J; Dienemann H
    Lung Cancer; 2010 Sep; 69(3):251-8. PubMed ID: 20537426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer.
    Deek MP; Tran PT
    Cancer J; 2020; 26(2):137-143. PubMed ID: 32205538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local Ablative Therapies in Oligometastatic NSCLC: New Data and New Directions.
    Lang P; Gomez DR; Palma DA
    Semin Respir Crit Care Med; 2020 Jun; 41(3):369-376. PubMed ID: 32450591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.
    Bansal P; Rusthoven C; Boumber Y; Gan GN
    Future Oncol; 2016 Dec; 12(23):2713-2727. PubMed ID: 27467543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Stereotactic body radiation radiotherapy for oligometastatic non-small cell lung cancer (NSCLC): A case report].
    Leduc C; Antoni D; Quoix É; Noël G
    Cancer Radiother; 2015 May; 19(3):192-7. PubMed ID: 25841992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.
    Juan O; Popat S
    Clin Lung Cancer; 2017 Nov; 18(6):595-606. PubMed ID: 28377206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereotactic Ablative Body Radiotherapy (SABR) in Pulmonary Oligometastatic/Oligorecurrent Non-small Cell Lung Cancer Patients: A New Therapeutic Approach.
    Agolli L; Valeriani M; Nicosia L; Bracci S; De Sanctis V; Minniti G; Enrici RM; Osti MF
    Anticancer Res; 2015 Nov; 35(11):6239-45. PubMed ID: 26504057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approach for oligometastasis in non-small cell lung cancer.
    Suzuki H; Yoshino I
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):192-6. PubMed ID: 26895202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Therapeutic options for oligoprogressive non-small cell lung cancer].
    Gustin P; Botticella A; Tselikas L; Mercier O; Le Péchoux C; Levy A
    Rev Mal Respir; 2019 Apr; 36(4):519-526. PubMed ID: 31010758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer.
    Holy R; Piroth M; Pinkawa M; Eble MJ
    Strahlenther Onkol; 2011 Apr; 187(4):245-51. PubMed ID: 21424513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of local therapy in oligometastatic non-small cell lung cancer.
    Isbell JM; Li BT; Gomez DR
    J Thorac Cardiovasc Surg; 2022 Mar; 163(3):819-825. PubMed ID: 34147255
    [No Abstract]   [Full Text] [Related]  

  • 15. To SABR or not to SABR? Indications and contraindications for stereotactic ablative radiotherapy in the treatment of early-stage, oligometastatic, or oligoprogressive non-small cell lung cancer.
    Shultz DB; Diehn M; Loo BW
    Semin Radiat Oncol; 2015 Apr; 25(2):78-86. PubMed ID: 25771411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The boundaries of curation].
    Debus J; Eberhardt W; Hoffmann H; Passlick B; Rübe C; Thomas M
    Onkologie; 2010; 33 Suppl 5():12-20. PubMed ID: 20523102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Body Radiotherapy and Ablative Therapies for Lung Cancer.
    Abbas G; Danish A; Krasna MJ
    Surg Oncol Clin N Am; 2016 Jul; 25(3):553-66. PubMed ID: 27261915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiosurgery and fractionated stereotactic radiotherapy in oligometastatic/oligoprogressive non-small cell lung cancer patients: Results of a multi-institutional series of 198 patients treated with "curative" intent.
    Buglione M; Jereczek-Fossa BA; Bonù ML; Franceschini D; Fodor A; Zanetti IB; Gerardi MA; Borghetti P; Tomasini D; Di Muzio NG; Oneta O; Scorsetti M; Franzese C; Romanelli P; Catalano G; Dell'Oca I; Beltramo G; Ivaldi GB; Laudati A; Magrini SM; Antognoni P;
    Lung Cancer; 2020 Mar; 141():1-8. PubMed ID: 31926440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer: Past, Present, and Future.
    McCall N; Higgins K
    Oncology (Williston Park); 2021 Jun; 35(6):313-319. PubMed ID: 34139791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgery for oligometastatic non-small cell lung cancer: long-term results from a single center experience.
    Congedo MT; Cesario A; Lococo F; De Waure C; Apolone G; Meacci E; Cavuto S; Granone P
    J Thorac Cardiovasc Surg; 2012 Aug; 144(2):444-52. PubMed ID: 22713303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.